# Parallel Bio

> Parallel Bio builds repeatable, patient-derived immune organoids and combines them with automation and computational analysis to help drug developers test safety, efficacy and population variation before human trials. The company sells studies to pharmaceutical and biotech partners, is building internal cancer and autoimmune programs, and says its platform has modeled more than 170 donor backgrounds, tested over 50 compounds and informed one Phase 1 trial.

- **Founded:** 2021
- **Headquarters:** Brisbane, United States
- **Founders:** Robert M. DiFazio (Co-Founder and Co-CEO), Juliana Hilliard (Co-Founder and Co-CEO)
- **Products:** Clinical Trial in a Dish, Human-first drug discovery, Precision medicine analytics, Biological foundation-model data
- **Notable:** Developed and patented methods for antibody-generating immune organoids that form features including germinal centers and B/T-cell zones., Launched Clinical Trial in a Dish in May 2024 with five pharmaceutical companies testing 20 candidates., Expanded to eight pharmaceutical partners and more than 50 drugs and immunotherapies by June 2025.

## Products & services

- **Clinical Trial in a Dish** — A commercial preclinical service using donor-derived lymph-node and spleen immune organoids to compare drug safety and efficacy across varied human backgrounds.
- **Human-first drug discovery** — An end-to-end program spanning disease modeling, target discovery and preclinical candidate evaluation using immune organoids, robotics and computational analysis.
- **Precision medicine analytics** — Population-response studies designed to reveal responder groups and support patient stratification.
- **Biological foundation-model data** — A growing proprietary dataset generated through automated perturbation of human immune models, intended to train predictive computational models.

## Achievements

- Developed and patented methods for antibody-generating immune organoids that form features including germinal centers and B/T-cell zones.
- Launched Clinical Trial in a Dish in May 2024 with five pharmaceutical companies testing 20 candidates.
- Expanded to eight pharmaceutical partners and more than 50 drugs and immunotherapies by June 2025.
- Completed its first announced partner preclinical study with Centivax for a universal influenza vaccine candidate.
- Reports modeling more than 170 unique patient backgrounds and 87% concordance with human outcomes.
- Reports that its data informed one Phase 1 trial.
- Named a World Economic Forum Technology Pioneer in 2026.
- Consolidated U.S. biological and computational operations in Brisbane, California, in 2026.

## Latest updates

- **2026-06** — Parallel Bio made Brisbane, California, its U.S. headquarters, consolidating biological and computational teams and adding five advisors across immunology, AI, drug development and cybersecurity.
- **2026-06** — The World Economic Forum selected Parallel Bio for its 2026 Technology Pioneers cohort.
- **2026-02** — The company disclosed a shift from partner-only testing toward an internal drug pipeline focused on cancer and autoimmune disease.
- **2025-06** — Parallel Bio raised a $21 million Series A led by AIX Ventures and announced eight pharma partners plus its first completed partner study with Centivax.

## Links

- Website: https://www.parallel.bio
- LinkedIn: https://www.linkedin.com/company/parallelbio
- Twitter/X: https://twitter.com/parallelbio

---

Profile page: https://yespress.io/parallel-bio
Published by YesPress — https://yespress.io
Last updated: 2026-09-26